Literature DB >> 9106330

Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection.

B L Ferry1, K I Welsh, M J Dunn, D Law, J Proctor, H Chapel, M H Yacoub, M L Rose.   

Abstract

The aetiologies of accelerated or transplant-associated coronary artery disease (TxCAD) following cardiac transplantation and chronic rejection following renal transplantation remain ill-defined. Previous studies have used Western blotting to demonstrate an association between the formation of anti-endothelial (anti-EC) antibodies and TxCAD after heart transplantation. However, Western blotting favours detection of cytosolic proteins. The objectives of this study were to determine whether flow cytometry, a method which detects antigens on the cell surface, could be used to detect anti-EC antibodies and also whether the observations would extend to renal transplant patients with chronic rejection. Flow cytometry was used to look for antibodies reactive with the surface antigens of macrovascular and microvascular endothelial cell lines in sera from 44 cardiac and 35 renal transplant recipients before and after transplantation. In addition, sera from normals (n = 20), patients with nontransplant CAD (n = 50) and patients with unrelated diseases (n = 40) were investigated. Of 23 cardiac recipients who had developed TxCAD at one or two years post-transplant, 61% had IgM and 13% had IgG anti-EC antibodies post-transplantation. In contrast, in 21 cardiac recipients who had not developed TxCAD 14% had IgM and 14% IgG anti-EC antibodies. There was little evidence for the presence of anti-EC antibodies in cardiac recipients before transplantation. Of 26 renal transplant recipients whose transplants failed due to chronic rejection, 42% had IgG and 19% IgM anti-EC antibodies post-transplantation. Of nine renal recipients whose grafts were either functioning normally or who had acutely rejected, none had IgG or IgM anti-EC antibodies either pre- or post-transplantation. The anti-EC antibodies were not found in normals and were rare (less than 4%) in the other disease groups; they do not appear to be autoantibodies. In conclusion, these results suggest the FACS assay could be an informative and rapid test to provide more information on chronic rejection following cardiac and renal transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106330     DOI: 10.1016/s0966-3274(97)80021-4

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  5 in total

1.  Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers.

Authors:  E R Rodriguez; Diane V Skojec; Carmela D Tan; Andrea A Zachary; Edward K Kasper; John V Conte; William M Baldwin
Journal:  Am J Transplant       Date:  2005-11       Impact factor: 8.086

2.  Screening of a HUVEC cDNA library with transplant-associated coronary artery disease sera identifies RPL7 as a candidate autoantigen associated with this disease.

Authors:  A T Linke; B Marchant; P Marsh; G Frampton; J Murphy; M L Rose
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

3.  De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection.

Authors:  Trudie A Goers; Sabarinathan Ramachandran; Aviva Aloush; Elbert Trulock; G Alexander Patterson; Thalachallour Mohanakumar
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

4.  Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Methods Mol Biol       Date:  2013

5.  Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection.

Authors:  Qiquan Sun; Zhihong Liu; Jinsong Chen; Huiping Chen; Jiqiu Wen; Dongrui Cheng; Leishi Li
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-25       Impact factor: 8.237

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.